A Haematologica Review of all Hemophilia Rebalancing Therapy Efforts

Here is an open-access article describing all efforts to develop effective rebalancing therapy, including Latarcibart®, a MOAB that suppresses PS, not previously described in FF: Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica. 2025 Dec 1;110(12):2902-2912. doi: 10.3324/haematol.2025.288245. PMID: 40820726; PMCID: PMC12666285. Abstract Treatment options for patients with hemophilia […]

Comments (0)

Bleeding Disorders

Sep 4 2026

george

Monitoring ADAMTS13 Deficiency: An Expert Rev. Hematology Review

Here is a current open-access article about ADAMTS13 deficiency: Binder NB, Depasse F, Spannagl M, et al. Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach. Expert Rev Hematol. 2026 Sep;19(9):1037-1057. doi: 10.1080/17474086.2026.2702550. PMID: 42461718. Abstract Introduction: ADAMTS13, a crucial enzyme in hemostasis that specifically cleaves von Willebrand factor […]

Bleeding Disorders

August 2026 QQ Summary: Coagulation Control Proteins

Our August 2026 QQ asked: “Which is NOT an endogenous coag control protein?” Our 29 participants answered… 1. Antithrombin: 1 (3%) 2. APC: 2 (7%) 3. TFPI: 4 (14%) 4. VKA: 22 (76%) VKA is the correct answer. VKA is the general term for the therapeutic anticoagulant warfarin (once called Coumadin®), which suppresses vitamin K […]

Bleeding Disorders

Hemophilia A Patient Satisfaction With Extended Half-life Altuviiio® Therapy

Click here for an open-access post hoc study report on patient satisfaction with once-weekly Altuviiio® (Efanesoctocog alfa) therapy: Spasov E, Quon D, Fukutake K, et al. Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial. Curr Ther Res Clin Exp. 2026;105:100839. doi: 10.1016/j.curtheres.2026.100839. […]

Bleeding Disorders

Type 2M VWD

A LinkedIn note by Shadi Tabibian, 2nd. Laboratory Hematologist and Director, Iranian Comprehensive Hemophilia Care Center; Deputy of Research, Blood Diseases Research Center, Iran University of Medical Sciences: Can a “normal” VWF activity-to-antigen ratio rule out Type 2 von Willebrand disease? Not always. One of the most interesting diagnostic lessons from this recent review is the […]

Bleeding Disorders

A Coag Conversation: 100 Years of VWD and Upcoming Advances: Conversation 3

On August 11, 2026, we posted the third and concluding conversation of “100 Years of Von Willebrand Disease and Upcoming Advances” with Robert F. Sidonio, Jr., MD, MSc. Click here for #3: Advanced Assays and von Willebrand Disease Management.

Bleeding Disorders

Effect of PCC on Bleeding Patients with FXa Inhibitor

Click here for a current study report on PCC therapy in patients with FXa inhibitors who are bleeding or needing surgery: Shaw JR, Gray H, Xu Y, et al. Effect of PCC on thrombin generation in patients on FXaI with bleeding or needing urgent surgery (GAUGE). Blood Adv. 2026;10(15):5378–88. doi: 10.1182/bloodadvances.2026020203. PMID: 42275536; PMCID: PMC13452292. […]

Bleeding Disorders

Events and Conferences: Bleeding Disorders Conference August 13–15

Thanks to Elaine Benoit, PBI’s marketing guru, for recent updates to our Events and Conferences Calendar. This week is the NBDF’s Bleeding Disorders Conference in Orlando, FL, USA, August 13–15. It’s not too late to register. Our colleagues at George King Bio-Medical will exhibit at booth 100. If you don’t see your hemostasis-related event or […]

Events

Review: AI Designing the Future of Hemostasis

Check your medical library for this review article on AI-based peptide design to modify the GPIbα-VWF interaction in platelet-type von Willebrand disease: Kazmirchuk TDD, Wang J, Corbette J, et al. Designing the future of hemostasis. Semin Thromb Hemost. 2026 Jun 9. doi: 10.1055/a-2885-4368. PMID: 42225137. Abstract Bleeding disorders arising from dysfunctional platelet-protein interactions pose a […]

Bleeding Disorders

July 2026 QQ Summary: VWD Therapeutic

Our July 2026 QQ asked: What VWD therapeutic is NOT a replacement factor? Our 24 participants responded… Desmopressin: 18 (75%) Humate P: 1 (4%) Vonvendi: 4 (17%) Wilate: 1 (4%) VWD bleeding is first managed by applying “PRICE:” protection, rest, ice, compression, and elevation. Next, desmopressin (DDAVP) is administered via injection, infusion, and, in Europe, […]

Comments (0)

Quick Question Archive

Bleeding Disorders

A Haematologica Review of all Hemophilia Rebalancing Therapy Efforts

Monitoring ADAMTS13 Deficiency: An Expert Rev. Hematology Review

August 2026 QQ Summary: Coagulation Control Proteins

Hemophilia A Patient Satisfaction With Extended Half-life Altuviiio® Therapy

Type 2M VWD

A Coag Conversation: 100 Years of VWD and Upcoming Advances: Conversation 3

Effect of PCC on Bleeding Patients with FXa Inhibitor

Events and Conferences: Bleeding Disorders Conference August 13–15

Review: AI Designing the Future of Hemostasis

July 2026 QQ Summary: VWD Therapeutic

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question